Minirin (Desmopressin Acetate)

Desmopressin acetate (Minirin) acts on the antidiuretic hormone pathway to manage water balance and haemostatic disorders.

• Central diabetes insipidus: reduces excessive urine output by enhancing water reabsorption in the kidneys.
• Nocturnal enuresis: decreases nighttime bedwetting episodes through improved urinary concentration.
• Mild hemophilia A (adjunct therapy): raises plasma factor VIII levels to aid clot formation.
• Von Willebrand disease (adjunct therapy): increases von Willebrand factor release, supporting haemostasis.

• Desmopressin acetate is a synthetic analogue of vasopressin that selectively binds to V2 receptors on the basolateral membrane of renal collecting‑duct cells. Activation of V2 receptors stimulates adenylate cyclase, raising intracellular cAMP, which promotes insertion of aquaporin‑2 water channels into the apical membrane, thereby increasing water reabsorption. In haemostatic indications, the drug triggers release of stored factor VIII and von Willebrand factor from endothelial cells.

Desmopressin acetate may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain in the head.
• Nasal congestion: sensation of stuffiness or blockage.
• Nausea: feeling of queasiness or urge to vomit.
• Mild hyponatraemia: low sodium levels causing fatigue or mild confusion.

Serious or Rare Side Effects

• Severe hyponatraemia: marked sodium depletion that can lead to seizures or coma.
• Thromboembolic events: blood clots such as deep‑vein thrombosis or pulmonary embolism.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing desmopressin acetate, clinicians should consider several safety precautions to minimise risk.

• Fluid restriction: limit excessive fluid intake to reduce hyponatraemia risk.
• Monitor electrolytes: regularly check serum sodium, especially in the elderly or those on diuretics.
• Cardiovascular disease: use caution in patients with heart failure or uncontrolled hypertension.
• Concomitant ADH‑active drugs: avoid or adjust dose when combined with other antidiuretic agents.
• Pregnancy and lactation: assess risk‑benefit before use as safety data are limited.
• Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and direct sunlight.

Desmopressin acetate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine or phenytoin: may reduce desmopressin effectiveness by increasing its metabolism.
• NSAIDs (e.g., ibuprofen, naproxen): can potentiate antidiuretic effect and increase hyponatraemia risk.
• Loop diuretics (e.g., furosemide): enhance water retention and electrolyte disturbances.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): desmopressin may augment clotting factor levels, affecting anticoagulant monitoring.
• SSRIs or SNRIs: combined effect on serotonin may increase risk of hyponatraemia.
• ACE inhibitors or ARBs: may contribute to fluid retention and electrolyte imbalance.